Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sarepta at new high on eteplirsen, Prosensa's drisapersen data

This article was originally published in Scrip

Executive Summary

Exactly one year after Sarepta Therapeutics saw its value triple based on 48-week, Phase II clinical trial data for its Duchenne muscular dystrophy (DMD) drug, the company's stock price reached a new high on 3 October based on the latest six-minute walk test (6MWT) and dystrophin results for eteplirsen and the competing DMD therapy drisapersen.

You may also be interested in...



Bristol’s CAR-T Strategy Comes Into Focus With Two Near-Term Filings

In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.

J&J Quickly Advances BCMA-Targeting CAR-T As JNJ-4528 Shows 100% Response

Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Topics

Related Companies

UsernamePublicRestriction

Register

SC022992

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel